- Home
- AIO vs PRAX Comparison
AIO vs PRAX Comparison
Compare AIO & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- PRAX
- Stock Information
- Founded
- AIO 2019
- PRAX 2015
- Country
- AIO United States
- PRAX United States
- Employees
- AIO N/A
- PRAX N/A
- Industry
- AIO Finance/Investors Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- PRAX Health Care
- Exchange
- AIO Nasdaq
- PRAX Nasdaq
- Market Cap
- AIO 808.3M
- PRAX 950.8M
- IPO Year
- AIO N/A
- PRAX 2020
- Fundamental
- Price
- AIO $24.67
- PRAX $45.94
- Analyst Decision
- AIO
- PRAX Strong Buy
- Analyst Count
- AIO 0
- PRAX 10
- Target Price
- AIO N/A
- PRAX $102.00
- AVG Volume (30 Days)
- AIO 141.5K
- PRAX 531.9K
- Earning Date
- AIO 01-01-0001
- PRAX 08-04-2025
- Dividend Yield
- AIO 9.05%
- PRAX N/A
- EPS Growth
- AIO N/A
- PRAX N/A
- EPS
- AIO N/A
- PRAX N/A
- Revenue
- AIO N/A
- PRAX $7,765,000.00
- Revenue This Year
- AIO N/A
- PRAX N/A
- Revenue Next Year
- AIO N/A
- PRAX $3,567.38
- P/E Ratio
- AIO N/A
- PRAX N/A
- Revenue Growth
- AIO N/A
- PRAX 338.45
- 52 Week Low
- AIO $15.09
- PRAX $26.70
- 52 Week High
- AIO $20.25
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- AIO 52.89
- PRAX 37.22
- Support Level
- AIO $24.54
- PRAX $46.16
- Resistance Level
- AIO $25.00
- PRAX $53.46
- Average True Range (ATR)
- AIO 0.37
- PRAX 3.70
- MACD
- AIO -0.04
- PRAX -1.57
- Stochastic Oscillator
- AIO 26.61
- PRAX 4.07
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.